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Comparing physicians’ and patients’
reporting on adverse reactions in
randomized trials on acupuncture—a
secondary data analysis
Thea Schwaneberg1, Claudia M. Witt2,3, Stephanie Roll2† and Daniel Pach2,3*†
Abstract
Background: We aimed to compare patients’ and physicians’ safety reporting using data from large acupuncture
trials (44,818 patients) and to determine associations between patient characteristics and reporting of adverse reactions.
Methods: Six pragmatic randomized trials with an additional non-randomized study arm that included those patients
who refused randomization were evaluated. Patients received acupuncture treatment for osteoarthritis of the hip or knee,
chronic neck pain, chronic low back pain, chronic headache, dysmenorrhea, or allergic rhinitis or asthma. Safety outcomes
were evaluated by questionnaires from both the physicians and the patients. To determine level of agreement between
physicians and patients on the prevalence of adverse reactions, Cohen’s kappa was used. With multilevel models
associations between patient characteristics and reporting of adverse reactions were assessed.
Results: Patients reported on average three times more adverse reactions than the study physicians: for bleeding/
haematoma, 6.7% of patients (n = 2458) vs. 0.6% of physicians (n = 255) and for pain, 1.7% of patients (n = 636) vs. 0.5%
of physicians (n = 207). We found only minor agreements between patients and physicians (maximum Cohen’s kappa:
0.50, 95% confidence interval [0.49;0.51] for depressive mood). Being a female and participation in the randomization
were associated with higher odds of reporting an adverse reaction.
Conclusions: In our study, patients’ and physicians’ reports on adverse reactions of acupuncture differed substantially,
possibly due to differences in patients’ and physicians’ questionnaires and definitions. For the assessment of safety, we
strongly support the inclusion of patients’ and physicians’ reports while ensuring standardization of data collection and
definitions.
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Background
Complementary and alternative medicine (CAM) therap-
ies are widely used to treat diseases [1–6]. Acupuncture in
particular has been shown to be useful for chronic pain
conditions [7–11]. Several studies were performed that
evaluated its efficacy, effectiveness, and safety [12–14].
The rate of patient consultations for CAM treatments has
been increasing [15]. As a result, the number of reported
adverse reactions might increase, especially those which
are not always avoidable, such as haematomas, nausea,
vomiting, and aggravation of symptoms [13, 16]. Previous
observational studies showed that acupuncture can be
considered a safe therapy [13, 17, 18], although some case
reports might give another impression [12, 19]. However,
serious life-threatening adverse reactions of acupuncture,
such as pneumothorax, are very rare [12, 13] but have
been published in some case reports [20]. Acupuncture
treatment for chronic low back and knee pain had been
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included in routine reimbursements by statutory health
insurances in Germany since 2007 [21–24].
Patients who are interested in receiving needle acupunc-
ture treatment should be informed about possible adverse
reactions for ethical reasons [12] and patient safety should
have a greater priority in acupuncture training [14]. How-
ever, the type and frequency of adverse reactions are diffi-
cult to compare between the various studies evaluating
acupuncture safety [12].
A limitation in many trials is that only health care pro-
fessionals, especially the physicians, have the responsibility
to document (serious) adverse events or adverse reactions
[25, 26]. The health care professionals have the profes-
sional competence regarding the evaluation of adverse
events or adverse reactions, whereas patients have good
individual knowledge about their own safety in healthcare
[27]. Only a few studies document the adverse reactions
by both physician and patients, e.g. [28] with the result
that frequency and severity can differ between physicians
and patients self-reports.
The aim was to compare patients’ safety reporting with
physicians’ safety reporting regarding the safety of acu-
puncture using data from several large acupuncture trials.
Furthermore, associations between patient characteristics
and reporting of adverse reactions were evaluated.
Methods
The present secondary data analysis is based on the
Acupuncture in Routine Care (ARC) studies that evalu-
ated the effectiveness of the addition of needle acupunc-
ture treatment [23] compared to usual care only. In those
trials, patients and physicians had to complete question-
naires to document safety parameters.
Study design
The ARC studies were part of the German model project
on acupuncture (‘Modellvorhaben Akupunktur’) funded
by the German statutory health insurances [8, 23, 29].
The project was performed to evaluate the effectiveness
of acupuncture treatment in routine medical care, as
well as its safety and cost effectiveness [23].
The ARC studies were large pragmatic randomized
trials with an additional non-randomized study arm in-
cluding those patients who refused randomization. The
recruitment period was from December 2000 to July
2004, and patients in both acupuncture treatment arms
(randomized and non-randomized) received 10–15 ses-
sions of needle acupuncture. Patients were eligible if
they were at least 18 years of age and had been suffering
from one of the following diseases for more than 6
months: osteoarthritis pain of the knee or hip, low back
pain, neck pain, headache, allergic rhinitis/asthma, or
dysmenorrhea. For each study, more detailed eligibility
criteria were employed [8, 30–34].
Randomization for needle acupuncture
Of the 50,473 pooled patients over all trials who were asked
if they agreed to be randomized, 11,486 agreed and were
randomized either to the acupuncture treatment group
(ACU, n = 5831) or to the control group (CON, n = 5655).
Participants who did not agree to the randomization were
part of the non-randomized acupuncture group (NR-ACU,
n = 38,987). Participants in the ACU and the NR-ACU
group started with the acupuncture treatment immediately,
whereas the CON group received acupuncture treatment
after 3 months. Needle acupuncture was performed by study
physicians with at least 140 h of acupuncture training [8].
Data collection
At baseline, patient age, gender, school graduation, highest
educational degree, occupational status, living situation,
diagnosis, health insurance status, and health insurance
type were assessed. Data collection regarding safety pa-
rameters was performed by questionnaires for patients
and their study physicians after a complete treatment
cycle.
If either the patient or the physician reported the pres-
ence of any side effect caused by acupuncture (adverse
reaction) in a short first questionnaire, both received a
detailed second questionnaire to report additional infor-
mation about it, including frequency, duration, time
between needle acupuncture and reaction, and treatment
need because of adverse reaction. All questions of the
questionnaires regarding the safety outcomes in the
ARC studies are listed in the supplementary material
(see additional file 1).
In the present analysis, only the acupuncture treatment
groups ACU and NR-ACU that received the immediate
acupuncture (n = 44,818) were considered because the
CON group received different types of questionnaires
regarding the safety parameters.
Safety parameters
We used the following definitions of the CONSORT state-
ment to differentiate the safety parameters: adverse events
are ‘harmful events that occur during a trial.’; in contrast,
adverse reactions are defined as ‘events for which a causal-
ity link to the tested intervention is well established and
strong enough (sensitive and specific)’ [35]. Several other
institutions in the healthcare sector such as the Food and
Drug Administration (FDA), Europeans Medicine Agency
(EMA), World Health Organization (WHO), or the
German Federal Institute for Drugs and Medical Devices
(BfArM) define adverse events and adverse reactions,
including drug reactions, in a similar, but not identical
way. The definitions are listed in the supplementary
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material (see additional file 2). In a review by Edwards and
Aronson, the differentiation was explained as follows: ‘The
terms adverse effect and adverse reaction are interchange-
able’ and ‘must be distinguished from adverse event.’ [36].
Statistical analysis
The primary analysis assessed the agreements for all ad-
verse reactions, which were classified into six categories:
i. BLEEDING/HAEMATOMA, ii. INFLAMMATION, iii.
PAIN, iv. VEGETATIVE SYMPTOMS, v. NERVE IRRI-
TATION/INJURIES, and vi. OTHERS. The frequencies
of the reported adverse reactions are listed, and a descrip-
tion in text form according to the European Commission
guidelines is given: very common (≥1/10), common (≥1/
100 to < 1/10), uncommon (≥1/1000 to < 1/100), rare (≥1/
10,000 to < 1/1000) and very rare (< 1/10,000) [37].
In addition, the agreement between patients’ and phy-
sicians’ reports was assessed using Cohen’s kappa (κ), a
coefficient that measures inter-rater agreement corrected
for agreement [38]. Kappa can take values from − 1 to 1
and can be interpreted in accordance with the five levels
by Landis and Koch: less than 0.00, poor; 0.00 to 0.20,
slight; 0.21 to 0.40, fair; 0.41 to 0.60, moderate; 0.61 to
0.80, substantial; and 0.81 to 1.00, almost perfect agree-
ment [39]. Note that the observed agreement is preva-
lence-dependent, but the agreement by chance is not.
To assess the association between self-reported adverse
reactions by patient or physician (yes/no) and patients’
characteristics, a logistic regression approach was used.
Because different participants were treated by the same
study physician, the data are clustered. The effect of clus-
tered data was estimated with the intraclass correlation
coefficient (ICC) and the design effect (DE) [40]. The ICC
estimates the correlation (similarity) of patients’ and phy-
sicians’ reports for patients of the same physician based
on a null model, which represents a regression model with
the variable for clustering only but no further covariates.
If the ICC is near 1 and the design effect is much
higher than 1, a clustered data structure is present. In
the multilevel model developed by Laird and Ware [41],
the clustered data structure can be taken into account
in the model with physicians as random effects and
patient characteristics as fixed effects. In a sensitivity
analysis, generalized estimated equation (GEE) models
by Liang and Zeger were used [42].
All analyses were performed with the statistics soft-
ware R (The R Foundation for Statistical Computing,
Vienna, Austria, version 3.1.1.) and the packages lme4
and geepack for clustered data regression based on the
data set in SPSS format (IBM SPSS Statistics 19). An
explorative significance level of 0.05 was used, and mul-
tiple test corrections were not applied. Note that the sig-
nificance of all results (or confidence intervals) should
be interpreted only exploratively. Furthermore, it should
be noted that for all the following results, missing data
were not imputed, and the analyses were based on the
respective available data.
Results
Patient characteristics
In the ARC studies, n = 44,818 patients received imme-
diate acupuncture treatment in the ACU and NR-ACU
treatment groups performed by 6727 physicians. Patients
who received acupuncture treatment were on average
48.5 ± 14.1 (mean ± standard deviation) years old, and
67.5% were women (Table 1). Of the included patients,
37.1% had at least a high school degree, 59.5% were
employees, and 83.8% live in a multi-person household.
Characteristics were similar in the ACU and NR-ACU
groups. The most common diagnoses for inclusion in the
study were headache and neck pain in both groups (ACU:
26.9%, 30.1%; NR-ACU: 29.6%, 26.7%, respectively). On
average, approximately seven patients were treated by one
study physician (6.6 ± 9.1, median = 4), with a range of
only one to more than 50 patients per physician.
Comparing patient and physician reports
The comparison of patient- and physician-reported ad-
verse reactions during the trial is provided as absolute
frequencies, proportions (%), and categories (Table 2). It
shows differences between patients’ and physicians’ ratings
for the main categories: BLEEDING/HAEMATOMA (pa-
tients: 2458 (6.7%), considered as ‘common’ vs. physicians:
255 (0.6%), ‘uncommon’), PAIN (636 (1.7%), ‘common’ vs.
207 (0.5%), ‘uncommon’), INFLAMMATION (136 (0.4%),
‘uncommon’ vs. 16 (0.04%), ‘rare’, NERVE IRRITATION/
INJURIES (90 (0.2%), ‘uncommon’ vs. 35 (0.1%), ‘rare’),
and OTHERS (420 (1.1%), ‘common’ vs. 158 (0.4%), ‘un-
common’). However, VEGETATIVE SYMPTOMS was
reported in the same frequency category by patients (229
(0.6%), ‘uncommon’) and physicians (136 (0.3%), ‘uncom-
mon’). The proportions of physicians’ to patients’ reports
for the adverse reaction categories are illustrated (Fig. 1).
Based on available data, 79% (n = 696) of the patients
stated that they had informed their physician about their
adverse reaction, whereas only 25% (n = 426) of the
physicians reported they had learned this from their pa-
tients. Most of the physicians (88.5%, n = 1512) had not
observed the adverse reactions themselves.
The agreements between patient- and physician-re-
ported adverse reactions as measured by Cohen’s kappa
differed for the various categories (Table 2). Depressive
mood had the highest kappa value of 0.50, which repre-
sents a moderate agreement between patient and phys-
ician. Anxiety (Cohen’s kappa 0.35), tinnitus (0.29), and
diarrhoea (0.29) also showed higher values. Many kappa
values, however, represented only slight agreement with
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Table 1 Baseline characteristics for the acupuncture in routine care (ARC) patients by the treatment groups randomized
acupuncture (ACU) and non-randomized acupuncture (NR-ACU)
Patient characteristics ACU
n = 5831
mean ± sd / n (%)
NR-ACU
n = 38,987
mean ± sd / n (%)
Total
n = 44,818
mean ± sd /
n (%)
Age in years 48.1 ± 13.8 48.5 ± 14.1 48.5 ± 14.1
Gender
Male 1883 (32.3) 12,688 (32.5) 14,571 (32.5)
Female 3948 (67.7) 26,299 (67.5) 30,247 (67.5)
Graduation in school
(available data n = 42,648)
9 years 1799 (31.9) 11,398 (30.8) 13,197 (30.9)
10 years 1672 (29.6) 10,227 (27.6) 11,899 (27.9)
12/13 years 1945 (34.5) 13,886 (37.5) 15,831 (37.1)
No graduation 47 (0.8) 234 (0.6) 281 (0.7)
Still going to school 23 (0.4) 143 (0.4) 166 (0.4)
Other graduation 154 (2.7) 1120 (3.0) 1274 (3.0)
Highest educational degree
(available data n = 41,941)
Apprenticeship 1858 (33.5) 11,612 (31.9) 13,470 (32.1)
Technical school 628 (11.3) 4318 (11.9) 4946 (11.8)
Technical college 981 (17.7) 6175 (17.0) 7156 (17.1)
University of applied sciences 685 (12.3) 4874 (13.4) 5559 (13.3)
University/college 745 (13.4) 5481 (15.1) 6226 (14.8)
No degree 301 (5.4) 1797 (4.9) 2098 (5.0)
Still in apprenticeship or 212 (3.8) 1164 (3.2) 1376 (3.3)
universityOther degree 141 (2.5) 969 (2.7) 1110 (2.6)
Occupational status
(available data n = 43,909)
Employee 3442 (59.9) 22,687 (59.4) 26,129 (59.5)
Self-employed 239 (4.2) 1905 (5.0) 2144 (4.9)
Unemployed 441 (7.7) 2235 (5.9) 2676 (6.1)
Welfare recipient 17 (0.3) 134 (0.4) 151 (0.3)
Student 123 (2.1) 901 (2.4) 1024 (2.3)
Pensioner 1295 (22.5) 8940 (23.4) 10,235 (23.3)
Others 189 (3.3) 1361 (3.6) 1550 (3.5)
Living situation
(available data n = 42,615)
Multiperson household 4739 (84.1) 30,960 (83.7) 35,699 (83.8)
Single person household 898 (15.9) 6018 (16.3) 6916 (16.2)
Diagnosis
Headache 1571 (26.9) 11,545 (29.6) 13,116 (29.3)
Asthma/allergic rhinitis 671 (11.5) 5342 (13.7) 6013 (13.4)
Low back pain 1449 (24.8) 8532 (21.9) 9981 (22.3)
Neck pain 1753 (30.1) 10,392 (26.7) 12,145 (27.1)
Dysmenorrhea 101 (1.7) 448 (1.1) 549 (1.2)
Arthritis 286 (4.9) 2728 (7.0) 3014 (6.7)
Health insurance status
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kappa values between 0.0 and 0.2 (not unexpected due to
small prevalence). For several adverse reactions, the kappa
value was estimated as agreement by chance (kappa = 0),
e.g., for local infection, generalized muscle pain, increase
in blood pressure, nerve injury, even though these adverse
reactions had above-average prevalence. Specific questions
on serious adverse events were included in the physicians’
questionnaires (see additional file 1), but frequencies were
too low to be analysed meaningfully.
Association between reported adverse reactions and
baseline characteristics
The ICC, estimating the similarity of patients’ and physi-
cians’ reports for patients of the same physician, was
0.12 based on patients’ reports and 0.90 for physicians’
reports. Therefore, 12 and 90% of the total variability is
between the patients treated by the same study physi-
cians, and this effect will be considered in the subse-
quent logistic regression analyses.
To assess associations between patients’ characteristics
and patient-reported or physician-reported adverse reac-
tions (yes/no), a multivariable multilevel logistic regression
was applied. Female patients showed higher odds of
reporting adverse reactions than males (OR 1.96, 95% CI
[1.76;2.17], Table 3). Patients who had agreed to be ran-
domized showed higher odds of reporting (1.24 [1.11;
1.39]) than patients who had not agreed to randomization.
Older patients (for a 10-year increase in age) reported
significantly less adverse reactions (0.82 [0.82;0.90]). Pa-
tients with a higher educational degree were more likely
to report adverse reactions (1.39 [1.22;1.59] for 12/13 years
in school; 1.16 [1.05;1.29] for academic degree in college/
university) than patients with a lower degree.
For physicians, the tendencies for associations are
similar, but the ORs are less precise (Table 3). Study
physicians reported significantly more adverse reactions
for female than for male patients (2.39 [1.87;3.15]), for
patients with higher degrees (2.32 [1.65;3.26] for 12/13
years in school), and for patients who had agreed to be
randomized before the studies (2.10 [1.59;2.78]). The dif-
ferences between the two statistical approaches, multi-
level model and GEE models, are negligible (GEE model
results not shown).
Discussion
We evaluated the reporting of adverse reactions in a
secondary data analysis of a large semi-randomized
controlled clinical trial on acupuncture for chronic pain
patients. We compared patients’ and physicians’ reports
regarding the frequency of adverse reactions and evaluated
their agreement. Overall, the patients reported on average
three times more adverse reactions than their physicians.
The most commonly reported adverse reaction was bleed-
ing/haematoma for both patients and physicians, similar
to a study by Witt et al. [13]. Despite this, many types of
adverse reactions were seldom reported, especially life-
threatening adverse reactions such as pneumothorax
[13, 20, 43]. No or only slight chance-corrected agree-
ments existed. However, differences in actual frequency
did not necessarily result in differences regarding fre-
quency category commonly used in product descriptions
[37]. Moreover, we observed that the chance of reporting
an adverse reaction either by the patient or the physician
was higher for patients who had agreed to be randomized
at baseline, i.e., who were willing to participate in an RCT,
were female, and had a higher education degree. Various
reasons might explain the difference between patients’ and
physicians’ reporting. In general, the physician is equipped
with more medical knowledge than the patient due to
long-term medical training and professional experience,
which can impact the reporting of adverse reactions, espe-
cially when the causality is vague. Indeed, it is feasible that
the patient is best positioned to report his or her own
symptoms [44].
The communication about the treatment and about its
potential adverse reactions, the motivation and time for
Table 1 Baseline characteristics for the acupuncture in routine care (ARC) patients by the treatment groups randomized
acupuncture (ACU) and non-randomized acupuncture (NR-ACU) (Continued)
Patient characteristics ACU
n = 5831
mean ± sd / n (%)
NR-ACU
n = 38,987
mean ± sd / n (%)
Total
n = 44,818
mean ± sd /
n (%)
(available data n = 43,909)
Member 4447 (77.4) 29,199 (76.5) 33,646 (76.6)
Spouse 1202 (20.9) 8256 (21.6) 9458 (21.5)
Child 97 (1.7) 708 (1.9) 805 (1.8)
Health insurance type
(available data n = 43,909)
Mandatory insured 3644 (63.4) 22,598 (59.2) 26,242 (59.8)
Voluntary insured 2102 (36.6) 15,565 (40.8) 17,667 (40.2)
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Table 2 Frequency of reported adverse reactions by patients and physicians sorted by categories in frequencies and proportions,
description in text form, and agreement as Cohen’s kappa (κ) coefficient with 95% confidence interval (CI) for 36,792 and 42,811
available data of 44,818 patients
Frequency n (%) Descriptiona Cohen’s kappa (κ)d
Patient reported
available data
n = 36,792
Physician reported
available data
n = 42,811
Patient reported
available data
n = 36,792
Physician reported
available data
n = 42,811
Kappa 95% CI
Bleeding/haematoma 2458 (6.681) 255 (0.596) common uncommon 0.11 0.10–0.11
Inflammation 136 (0.370) 16 (0.037) uncommon rare
Inflammation 129 (0.351) 13 (0.030) uncommon rare 0.09 0.08–0.10
Local infection 7 (0.019) 3 (0.007) rare very rare 0.00 −0.01 − 0.01
Pain 636 (1.729) 207 (0.484) common uncommon
Other pain 215 (0.584) 38 (0.090) uncommon rare 0.08 0.07–0.09
Headache 197 (0.535) 49 (0.114) uncommon uncommon 0.21 0.20–0.21
Aggravation of symptoms 89 (0.242) 65 (0.152) uncommon uncommon 0.09 0.08–0.10
Local muscle pain 73 (0.198) 21 (0.049) uncommon rare 0.02 0.01–0.03
Strong pain during needling 61 (0.166) 33 (0.077) uncommon rare 0.02 0.01–0.03
Generalized muscle pain 1 (0.003) 1 (0.002) very rare very rare 0.00 −0.01 − 0.01
Vegetative symptoms 229 (0.622) 136 (0.320) uncommon uncommon
Vertigo 78 (0.212) 31 (0.072) uncommon rare 0.16 0.15–0.17
Other cardiovascular
disturbance
62 (0.169) 62 (0.145) uncommon uncommon 0.16 0.15–0.17
Nausea 48 (0.130) 17 (0.040) uncommon rare 0.21 0.20–0.22
Unconsciousness 10 (0.027) 8 (0.019) rare rare 0.27 0.26–0.28
Breathing difficulties 9 (0.024) 6 (0.014) rare rare 0.00 −0.01 − 0.01
Sweating 9 (0.024) 5 (0.012) rare rare 0.18 0.17–0.19
Tachycardia 8 (0.022) 6 (0.014) rare rare 0.18 0.17–0.19
Increase in blood pressure 2 (0.005) 1 (0.002) very rare very rare 0.00 −0.01 − 0.01
Palpitationsb 1 (0.003) 0 (0.000) very rare – 0 –
Constipationb 1 (0.003) 0 (0.000) very rare – 0 –
Enterospasmb 1 (0.003) 0 (0.000) very rare – 0 –
Nerve irritation/injuries 90 (0.245) 35 (0.082) uncommon rare
Hypaesthesia 44 (0.120) 7 (0.016) uncommon rare 0.04 0.03–0.05
Nerve irritations 24 (0.065) 4 (0.009) rare very rare 0.08 0.07–0.08
Paraesthesia 12 (0.033) 22 (0.051) rare rare 0.06 0.05–0.07
Nerve injury 5 (0.013) 2 (0.005) rare very rare 0.00 −0.01 − 0.01
Paresis b 5 (0.013) 0 (0.000) rare – 0 –
Others 420 (1.142) 158 (0.369) common uncommon
Fatigue 80 (0.217) 16 (0.037) uncommon rare 0.16 0.15–0.17
Swelling 70 (0.190) 11 (0.026) uncommon rare 0.12 0.11–0.12
Other dermal phenomena 36 (0.098) 15 (0.035) rare rare 0.26 0.25–0.27
Other neurological
complaints
27 (0.073) 1 (0.002) rare very rare 0.00 0.00–0.00
Itching 24 (0.065) 3 (0.007) rare very rare 0.09 0.08–0.09
Worsening health state 23 (0.063) 10 (0.023) rare rare 0.07 0.06–0.08
Redness 21 (0.057) 16 (0.037) rare rare 0.06 0.05–0.07
Collapse 18 (0.049) 17 (0.040) rare rare 0.19 0.18–0.20
Restricted movements 15 (0.041) 1 (0.002) rare very rare 0.00 −0.01 − 0.01
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reporting, the disease treated, and the general educational
background might also impact reporting. Furthermore,
the method of documenting adverse reactions might have
an impact. In our study, the patient’s question used to spe-
cify adverse reactions offered tick boxes for bleeding/
haematoma and local inflammation as examples, whereas
the physician’s included a free text answer to this
question. This and the fact that these reactions might not
be considered side effects by acupuncturists from the per-
spective of traditional Chinese medicine have possibly
contributed to the differences in these categories. Al-
though we included a comparably large number of cases
and treatments with more than 44,000 chronic pain
patients, conclusions regarding the specific frequency of
Table 2 Frequency of reported adverse reactions by patients and physicians sorted by categories in frequencies and proportions,
description in text form, and agreement as Cohen’s kappa (κ) coefficient with 95% confidence interval (CI) for 36,792 and 42,811
available data of 44,818 patients (Continued)
Frequency n (%) Descriptiona Cohen’s kappa (κ)d
Patient reported
available data
n = 36,792
Physician reported
available data
n = 42,811
Patient reported
available data
n = 36,792
Physician reported
available data
n = 42,811
Kappa 95% CI
Other mood swings 13 (0.035) 8 (0.019) rare rare 0.11 0.09–0.12
Tinnitus 10 (0.027) 4 (0.009) rare very rare 0.29 0.28–0.30
Vomiting 9 (0.024) 4 (0.009) rare very rare 0.17 0.16–0.18
Feeling of coldness 8 (0.022) 3 (0.007) rare very rare 0.00 −0.01 − 0.01
Menstrual problems 8 (0.022) 3 (0.007) rare very rare 0.25 0.24–0.26
Anxiety 8 (0.022) 11 (0.030) rare rare 0.35 0.34–0.36
Sleep disturbance 6 (0.016) 2 (0.005) rare very rare 0.00 −0.01 − 0.01
Disturbed vision 6 (0.016) 2 (0.005) rare very rare 0.00 -0-01 − 0.01
Diarrhoea 5 (0.014) 3 (0.007) rare very rare 0.29 0.28–0.30
Needle forgotten 4 (0.011) 1 (0.002) rare very rare 0.00 −0.01-0.01
Imbalance 4 (0.011) 1 (0.002) rare very rare 0.00 -0.01-0.01
Other gastrointestinal
complaints
4 (0.011) 3 (0.007) rare very rare 0.00 -0.01-0.01
Joint problems 3 (0.008) 3 (0.007) very rare very rare 0.00 -0.01-0.01
Depressive mood 3 (0.008) 2 (0.005) very rare very rare 0.50 0.49–0.51
Eye irritation 3 (0.008) 1 (0.002) very rare very rare 0.00 -0.01-0.01
Burns after moxibustion 2 (0.005) 6 (0.014) very rare rare 0.00 -0.01-0.01
Systemic infection 2 (0.005) 4 (0.009) very rare very rare 0.00 -0.01-0.01
Poor concentrationb 2 (0.005) 0 (0.000) very rare – 0 –
Gastrospasm 2 (0.005) 1 (0.002) very rare very rare 0.00 -0.01-0.01
Vascular injuriesb 1 (0.003) 0 (0.000) very rare – 0 –
Nightmaresb 1 (0.003) 0 (0.000) very rare – 0 –
Restlessness/nervousness 1 (0.003) 3 (0.007) very rare very rare 0.00 -0.01-0.01
Shiveringb 1 (0.003) 0 (0.000) very rare – 0 –
Pneumothoraxc 0 (0.000) 1 (0.000) – very rare 0 –
Other organ injuriesc 0 (0.000) 1 (0.000) – very rare 0 –
Disorientationc 0 (0.000) 1 (0.000) – very rare 0 –
Average kappa (κ) 0.21 0.20–0.22
Note: a kappa coefficient can only be calculated if both the patient and physician reported a reaction; kappa values above 0.2 indicate fair agreement and are
marked in bold
aDescription of the frequencies in text form according to the guideline of the European Commission to describe the frequencies of adverse effects or reactions of
medical products: very common: (≥1/10), common (≥1/100 to < 1/10), uncommon (≥1/1000 to < 1/100), rare (≥1/10,000 to < 1/1000) and very rare
(< 1/10,000) [37].
bReported only by patient
cReported only by physician
dInterpretation of Cohen’s kappa (κ): < 0, poor; 0–0.20, slight; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, substantial; 0.81–1.00, almost perfect; 1,
perfect agreement
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adverse reactions in acupuncture should be drawn very
carefully when they are only based on our present study.
For the evaluation of acupuncture safety, other even larger
studies were specifically designed, performed and pub-
lished [13, 17, 45].
This study has some limitations. Firstly, we used sec-
ondary data from December 2000 to July 2004 which
were not primarily designed to evaluate the differences
between physicians’ and patients’ reporting of adverse
reactions. The primary aim of the ARC trials was the
evaluation of efficacy, while evaluating safety was only
one of many secondary outcomes. We did not adjust for
multiple comparisons.
A further problem is that the patients and physicians
do not rate completely independent because many
adverse reactions are invisible to the study physician and
have to be reported by the patient to the physician first,
and the physician might explain the definition of adverse
reactions to the patient. Hence, physician’s reports based
on the patient’s reports could validate the patient’s
report, assuming the physician’s assessment can serve as
the gold standard. However, this might cause under-
reporting, whereas over-reporting of too many unjusti-
fied adverse reactions could cause difficulties when
explaining the safety characteristics of the intervention
in a real life setting. A further limitation of our study is
that the assessment of adverse reactions was based on
retrospective self-reports, which can be influenced by
recall bias [46]. The lack of differentiation between ad-
verse events and adverse reactions caused by acupunc-
ture could be an additional reason for the differential
reporting. Definitions according to WHO, FDA or EMA
differ by nuance [35, 47–49]. In the literature, these
terms are sometimes used synonymously (e.g., [50, 51]).
The exact definitions of reputable institutions are listed
in the supplemental material (see additional file 2).
In the physicians’ questionnaire in this study, we in-
cluded a definition for an adverse reaction that referred to
its noxious and unintended character to separate it from
an adverse event. In contrast, the patient’s questionnaire
did not include any explanation to improve clarity and
usability of the questionnaire and because only adverse
reactions and not adverse events had to be reported by
patients. The difference in the questionnaires may to some
extent explain differences in reporting of some adverse
reactions, such as bleeding/haematoma that is sometimes
intended by acupuncturists or pain, but not the differences
for adverse reactions such as vertigo or fatigue. For future
studies, we recommend a similar application of written
definitions for both the physician and the patient ques-
tionnaire. However, tick boxes or free text should also be
applied in a similar way. Not only who assesses but also
how the assessment is performed can cause large differ-
ences in reported rates as shown in an RCT by Bent et al.
[52]. This study compared three methods (1. an open-
ended question, 2. an open-ended, defined question, and
Fig. 1 Physicians (light grey inner circle) to patients (outer circle) reported adverse reactions in six categories: bleeding/haematoma (n = 255
physicians and n = 2458 patients reports, the ratio represents 10.4%), inflammation, pain, vegetative symptoms, nerve irritation/injuries, and others
(for numbers see Table 2)
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3. a checklist of 53 common side effects) to assess adverse
events experienced by study participants. The percentage
of patients reporting any adverse events was much higher
in the group using the checklist (77%) than in the first
(14%) or second group (13%). This demonstrates the com-
plexity of reporting and standards.
Strikingly, most of the studies on the safety character-
istics of acupuncture are either based on therapists’/
Table 3 Association between patient characteristics and reporting of adverse reaction (yes/no) from patients and physicians
(multivariable multilevel logistic regression, yielding adjusted* odds ratios and 95% confidence intervals (CI))
Patient characteristics Patient report adverse reaction
available data n = 36,792
(yes/no: 3368/33,424)
Physician report adverse reaction
available data n = 41,822
(yes/no: 651/41,171)
Odds ratio 95% CI Odds ratio 95% CI
Age (10 year increase) 0.82 0.82–0.90 1.00 0.90–1.10
Gender
Female (vs. male) 1.96 1.76–2.17 2.39 1.87–3.15
Graduation in school years
(reference: 9 years)
12/13 years 1.39 1.22–1.59 2.32 1.65–3.26
10 years 1.26 1.12–1.42 1.17 0.87–1.59
Other or no graduation 1.18 0.94–1.48 1.15 0.64–2.08
Highest degree
(reference: apprenticeship)
College/university 1.16 1.04–1.29 1.03 0.79–1.33
Technical school/college 1.15 1.01–1.31 0.57 0.41–0.79
Other or no degree 0.90 0.77–1.05 0.98 0.68–1.41
Occupational status
(reference: employed)
Unemployed or
welfare-recipient
1.21 1.03–1.41 0.42 0.25–0.71
Student or other 1.19 1.01–1.40 1.53 1.06–2.21
Pensioner 1.05 0.91–1.21 0.66 0.46–0.96
Living situation
Multiperson household
(vs. single person)
0.93 0.83–1.03 1.12 0.85–1.47
Randomization
Randomized
(vs. non-randomized)
1.24 1.11–1.39 2.10 1.59–2.78
Diagnosis
(reference: headache)
Asthma/allergic rhinitis 1.03 0.91–1.16 0.97 0.70–1.33
Low back pain 0.85 0.76–0.96 0.69 0.51–0.95
Neck pain 1.01 0.91–1.12 1.09 0.83–1-41
Dysmenorrhea 0.86 0.62–1.19 0.71 0.29–1.71
Arthritis 0.85 0.67–1.07 0.40 0.21–0.76
Health insurance status
(reference: member)
Spouse 1.00 0.90–1.13 0.90 0.67–1.20
Child 1.14 0.83–1.57 0.61 0.25–1.50
Health insurance type
Voluntary insured
(vs. mandatory)
0.93 0.85–1.02 0.83 0.65–1.05
*Adjusted for all other factors listed
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physicians’ or patients’ reporting but not of both [53–
56]. Fromme et al. investigated the clinician reporting of
adverse reactions during chemotherapy [57]. In the
study, 37 men with prostate cancer reported their ad-
verse events, and the agreements with the study physi-
cians using Cohen’s kappa was determined. The total
Cohen’s kappa value was 0.15, which represents slight
agreement, and was similar to our results. For rheuma-
toid arthritis, the reporting of adverse drug events
between patients (n = 4246) and physicians differed; even
for serious adverse events, the agreement was only 37%
[58], whereas patients reported more events, which is
similar to our results.
In a study comparing adverse events reported in post-
discharge patient interviews with adverse events detected
by medical record review, the agreement for adverse events
(kappa = 0.20) and serious adverse events (kappa = 0.33)
was low and comparable to our agreement results [59]. In
contrast, in an oncology study in 2005, the agreement of
400 patients with their clinicians was higher (kappa up to
0.5) [60]. Especially, for observable reactions, the agree-
ment was higher than for subjective ones [60].
A standardized reporting and documentation of both
adverse events and reactions is essential [35, 61, 62]. For
drug safety, the FDA developed a reporting system in
1998 [63]. For non-interventional pain studies, there are
guidelines as CONSORT or ACTTION to document ad-
verse reactions, but even these guidelines do not provide
a high degree of detail [64]. In oncology, there are cur-
rently some documentation tools to combine the analytical
and professional side of physicians and individual patient’s
side using quality of life, symptoms, and patient-reported
outcomes to enhance patient-clinician communication and
to enable early detection of toxicities [60, 65]. In a British
acupuncture study, the adverse events were monitored in a
standardized way with self-reports by patient at each
acupuncture session [66]. However, the documentation of
safety by patient reports is still not standardized in clinical
trials and health care. Even for the obligatory adverse drug
reaction documentation, various information systems are
used [67]. Standardized electronic web-based documenta-
tion software or intuitive mobile apps in contrast to clas-
sical methods (phone, questionnaire) could support the
complete and harmonized documentation of adverse reac-
tions [67, 68]. Further, it is important to differentiate
between adverse events and adverse reactions and to evalu-
ate a possible causal link to the intervention.
We think that both patients’ and physicians’ reports
should be included when evaluating safety aspects of a
medical intervention while electronic documentation
tools might support this. Patients (or their relatives) can
play an important role in signalling safety aspects in
clinical trials as well as in routine care [62, 69] and can
help the patient-centred approach in the future.
Regular communication between the physicians, other
clinical staff and patients and the standardization of doc-
uments, including clarification of definitions, might help
to minimize differences.
Conclusions
In our study, patients’ and physicians’ reports of adverse
reactions of acupuncture differed substantially, possibly
due to differences in patients’ and physicians’ question-
naires and definitions. The use of frequency categories has
been shown to be useful and able to compensate for
reporting differences. For the assessment of safety param-
eters, we strongly support the inclusion of both patients’
and physicians’ reports while ensuring standardization of
data collection and definitions.
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